Francesca Simionato

Medicine · Health Sciences

23h-index1.6kcitations137works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(39), Pancreatic and Hepatic Oncology Research(34), Cancer Research and Treatments(30), Cancer Cells and Metastasis(21), Gastric Cancer Management and Outcomes(20)

Publications137 total

Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO
Annals of Oncology·2025· 4 citedOpen Access
Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)
Journal of Thoracic Oncology·2024· 4 cited
P2.16A.01 Actionable Alterations Identification in NSCLC by Comprehensive Genomic Profiling for Clinical Trial Enrollment: EPROPA
Journal of Thoracic Oncology·2024
Implementation of a MSRE ddPCR method for the detection of methylated <i>WIF1</i> and <i>NPY</i> genes in colorectal cancer patients
Tumori Journal·2024
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial
Frontiers in Oncology·2024· 6 citedOpen Access
Actionable Non-Small Cell Lung Cancer Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients with Advanced Lung Cancer (Epropa)
SSRN Electronic Journal·2024Open Access
142P The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Annals of Oncology·2023Open Access
EP13.03-02 Improved Long-Term Survival and Less Chemotherapy in Extended-SCLC Patients: A Real-World Study in the Immunotherapy Era
Journal of Thoracic Oncology·2023· 1 citedOpen Access
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
Liver International·2023· 111 citedOpen Access
Data from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
2023Open Access
Figure S4 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
2023Open Access
Data from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
2023Open Access
Figure S6 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
2023Open Access
Figure S1 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
2023Open Access
Figure S1 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
2023Open Access
Figure S2 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
2023Open Access
Figure S8 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
2023Open Access
Figure S5 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
2023Open Access
Figure S7 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
2023Open Access
Figure S5 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Davide Melisi(24), Giuseppe Aprile(16), Valeria Merz(14), Camilla Zecchetto(14), Giampaolo Tortora(14), Raffaela Santoro(13), Mario Scartozzi(11), Carmine Carbone(10), Geny Piro(10), Sara Lonardi(9), Aldo Scarpa(9), Lorenzo Fornaro(8), Margherita Rimini(7), Francesca Ratti(7), Luca Aldrighetti(7), Stefano Cascinu(7), Alessandro Cappetta(7), Andrea Pretta(6), Andrea Casadei‐Gardini(6), Teresa Macarulla(6)